Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$448,040.00

Nanoparticle-based anti-Myc cancer therapeutics

FY 2013-14

Summary
We are designing new drugs that can combat cancer. These drugs are based on natural proteins, which are abundant in your body and make your body function. We take these building blocks and design super protein drugs. One of our drugs interferes with a known problem in cells that can lead to cancer. Our team is now focusing on how to use nanotechnology, which are tiny carrier particles that can deliver the drug to cancer cells. Once inside the cells, the drug can interfere with cancer networks. We have shown that our strategy can work in human cancer cell experiments, and we are now aiming to test our drugs in mice. The Canadian company BioVectra is our partner and is involved in our studies with the hope of advancing our new drug to human cancer patients. They are also excited to work with us, because we can take the concepts described in this work and design additional drugs targeting other proteins that cause problems in many human diseases.
Program
Collaborative Health Research Projects (NSERC partnered)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
296093
Name
Shin Jumi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Nanoparticle-based anti-Myc cancer therapeutics
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$448,040
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Anti-Cancer Therapeutics; B1h; Chip & Chip-Chip; Enhancer Box (E-Box); Mammalian Cell Lines; Myc-Dependent Transformation; Myc/Max Transcription Factors; Nanotechnology & Nanodelivery; Protein Design & Directed Evolution; Protein:Dna Interactions; Y1h; Y2h
Abstract
We are designing new drugs that can combat cancer. These drugs are based on natural proteins, which are abundant in your body and make your body function. We take these building blocks and design super protein drugs. One of our drugs interferes with a known problem in cells that can lead to cancer. Our team is now focusing on how to use nanotechnology, which are tiny carrier particles that can deliver the drug to cancer cells. Once inside the cells, the drug can interfere with cancer networks. We have shown that our strategy can work in human cancer cell experiments, and we are now aiming to test our drugs in mice. The Canadian company BioVectra is our partner and is involved in our studies with the hope of advancing our new drug to human cancer patients. They are also excited to work with us, because we can take the concepts described in this work and design additional drugs targeting other proteins that cause problems in many human diseases.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Shin, Jumi; Chan, Warren C; Penn, Linda Z
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $448,040~ $0~